EMEA-002727-PIP01-19-M01
Key facts
| Active substance |
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0070/2021
|
| PIP number |
EMEA-002727-PIP01-19-M01
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of melanoma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb International Corporation
E-mail: medical.information@bms.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-002727-PIP01-19-M01
|
| Compliance opinion date |
10/09/2021
|
| Compliance outcome |
positive
|